A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment ofHelicobacter pyloriInfection: A Pilot Study
- 20 March 2015
- journal article
- research article
- Published by Wiley in Helicobacter
- Vol. 20 (5), 390-396
- https://doi.org/10.1111/hel.12209
Abstract
Tetracycline-containing triple therapy has been suggested as an alternative first-line therapy for H. pylori infection.To evaluate the effect of two dosages of doxycycline (DOX) associated with amoxicillin and esomeprazole with and without bismuth subcitrate as first-line treatment of H. pylori infection.Helicobacter pylori-positive patients underwent a 10-day therapy randomized into four groups: Group A received esomeprazole, amoxicillin, and DOX-100 mg b.i.d. (EAD-100), Group B a quadruple therapy with esomeprazole, amoxicillin, DOX-100 mg b.i.d. and bismuth subcitrate (EADB-100), Group C a triple therapy with esomeprazole, amoxicillin, and DOX-200 mg b.i.d. (EAD-200) and Group D a quadruple therapy with esomeprazole, amoxicillin, DOX-200 mg b.i.d., and bismuth subcitrate (EADB-200). Success was accessed by (13) C urea breath test 2 months after the end of treatment. The number of patients to be recruited for each group had to be at least 50 subjects. Treatment success of 80% or less was considered unacceptable. Stopping rules therefore were anytime six failures had occurred.In the EAD-100 group and in EAD-200 group, the recruitment was stopped at the 14th and 15th patient, respectively. Fifty-two patients entered in the EADB-100 group and 51 in the EADB-200 group. Intention to treat eradication was in EADB-100 group 46/52 (88.5%, 95% CI 76.6-95.6); in the EADB-200 group 47/51 (92.1%, 95% CI: 81.1-97.8) (n.s.). Side effects were absent.The adjunction of bismuth subcitrate to a triple therapy that includes esomeprazole, amoxicillin, and DOX in patients who are treated for the first time for the H. pylori infection potentiates the therapeutic effect. This regimen, however, deserves to be optimized in terms of duration and dose of DOX.Keywords
This publication has 47 references indexed in Scilit:
- The Optimal First-Line Therapy ofHelicobacter pyloriInfection in Year 2012Gastroenterology Research and Practice, 2012
- A Randomized Study Comparing Levofloxacin, Omeprazole, Nitazoxanide, and Doxycycline versus Triple Therapy for the Eradication of Helicobacter pyloriThe American Journal of Gastroenterology, 2011
- Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trialThe Lancet, 2011
- Bismuth improves PPI-based triple therapy for H. pylori eradicationNature Reviews Gastroenterology & Hepatology, 2010
- Efficient Identification and Evaluation of Effective Helicobacter pylori TherapiesClinical Gastroenterology and Hepatology, 2009
- The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradicationEuropean Journal of Internal Medicine, 2009
- Issues in Outcomes Research: An Overview of Randomization Techniques for Clinical TrialsJournal of Athletic Training, 2008
- Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportGut, 2007
- Helicobacter pyloriDetection and Antimicrobial Susceptibility TestingClinical Microbiology Reviews, 2007
- Colloidal Bismuth SubcitrateDrugs, 1988